Immunologic aspects of hypoplastic myelodysplastic syndrome

Seminars in Oncology

Volumn 38, Issue 5, 2011, Pages 667-672

  Calado, Rodrigo T ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; CYTOKINE; DICER; FLICE INHIBITORY PROTEIN; GAMMA INTERFERON; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APLASTIC ANEMIA; APOPTOSIS; ARTICLE; BONE MARROW DEPRESSION; CYTOPENIA; CYTOTOXIC T LYMPHOCYTE; DIFFERENTIAL DIAGNOSIS; DRUG WITHDRAWAL; ERYTHROPOIESIS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HYPOPLASTIC MYELODYSPLASTIC SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; LEUKEMIA; LEUKEMOGENESIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT;

ANEMIA, APLASTIC; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYELODYSPLASTIC SYNDROMES; PATIENT SELECTION; STEM CELL NICHE;

EID: 80053195109     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.04.006     Document Type: Article

References (51)

1. - syndrome gene by RNA interference screen Nature 451 2008 335 337
2. A. List, S. Kurtin, and D.J. Roe Erficacy of lenalidomide in myelodystplastic syndromes N Engl J Med 352 2005 549 557
3. WHO classification of tumours of haematopoietic and lymphoid tissues 4th ed. 2008 International Agency for Research on Cancer Lyon, France
4. D. Marisavljevic, V. Cemerikic, Z. Rolovic, D. Boskovic, and M. Colovic Hypocellular myelodysplastic syndromes: clinical and biological significance Med Oncol 22 2005 169 175 (Pubitemid 41003450)
5. I. Lorand-Metze, M.P. Pinheiro, E. Ribeiro, E.V. De Paula, and K. Metze Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications Leuk Res 28 2004 587 594 (Pubitemid 38548855)
6. G. Yue, S. Hao, and O. Fadare Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome Leuk Res 32 2008 553 558 (Pubitemid 351255556)
7. E.M. Sloand, C. Wu, P. Greenberg, N.S. Young, and A.J. Barrett Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy J Clin Oncol 26 2007 2505 2511
8. J.M. Bennett, and A. Orazi Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach Haematologica 94 2009 264 268
9. E.M. Sloand, and A.J. Barrett Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success Hematol Oncol Clin North Am 24 2010 331 341
10. M. Otawa, Y. Kawanishi, O. Iwase, N. Shoji, K. Miyazawa, and K. Ohyashiki Comparative multi-color flow cytometric analysis of cell surface antigens in bone marrow hematopoietic progenitors between refractory anemia and aplasti anemia Leuk Res 24 2000 359 366 (Pubitemid 30122383)
11. J.W. Choi, M. Fujino, and M. Ito F-blast is a useful marker for differentiating hypocellular refractory anemia from aplastic anemia Int J Hematol 75 2002 257 260 (Pubitemid 43014056)
12. J.P. Maciejewski, C. Rivera, H. Kook, D. Dunn, and N.S. Young Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored protein-deficient clones Br J Haematol 115 2001 1015 1022 (Pubitemid 34042927)
13. H. Wang, T. Chuhjo, S. Yasue, M. Omine, and S. Nakao Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome Blood 100 2002 3897 3902 (Pubitemid 35396854)
14. N.S. Young, and J.P. Maciejewski Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: this little PIG-A goes "why? why? why?" J Clin Invest 106 2000 637 641
15. S.A. Wang, O. Pozdnyakova, and J.L. Jorgensen Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats Haematologica 94 2009 29 37
16. R.T. Calado, and N.S. Young Telomere maintenance and human bone marrow failure Blood 111 2008 4446 4455
17. B.P. Alter, N. Giri, S.A. Savage, and P.S. Rosenberg Cancer in dyskeratosis congenita Blood 113 2009 6549 6557
18. R.T. Calado, J.A. Regal, and D.E. Kleiner A spectrum of severe familal liver disorders associate with telomerase mutations PLoS One 4 2009 e7926
19. Cooper JN, Calado R, Wu C, Scheinberg P, Young NS. Telomere length of peripheral blood leukocytes predicts relapse and clonal evolution after immunosuppressive therapy in severe aplastic anemia [abstract]. Blood. 208;112:442.
20. H. Yamaguchi, G.M. Baerlocher, and P.M. Lansdorp Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome Blood 102 2003 916 918 (Pubitemid 36917783)
21. R.T. Calado, C. Prince, N.R. Peterson, N.S. Young, and J.P. Maciejewski Mutations in the telomerase reverse transcriptase gene predisposes to myelodysplastic syndromes [abstract] Blood 114 2009 415
22. C.A. Ortmann, C.M. Niemeyer, A. Wawer, W. Ebell, I. Baumann, and C.P. Kratz TERC mutations in children with refractory cytopenia Haematologica 91 2006 707 708 (Pubitemid 43799476)
23. H. Engin, I. Kuzu, Y. Ustundag, S. Aydemir, A.G. Akoz, and D. Kilincarslan Dyskeratosis congenita associated with hypocellular myelodysplastic syndrome: a case report Am J Med Sci 334 2007 206 208 (Pubitemid 47414994)
24. V. Shetty, S. Mundle, and S. Alvi Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes Leuk Res 20 1996 891 900 (Pubitemid 27042322)
25. M. Kitagawa, I. Saito, and T. Kuwata Overexpression of tumor necrosis factor (TNF)-α and interferon (INF)-gamma by bone marrow cells from patients with myelodysplastic syndromes Leukemia 11 1997 2049 2054 (Pubitemid 28043688)
26. G. Stifter, S. Heiss, G. Gastl, A. Tzankov, and R. Stauder Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis Eur J Haematol 75 2005 485 491 (Pubitemid 41687782)
27. G.E. Verhoef, P. Schouwer, J.L. Ceuppens, J.O. Van Damme, W. Goossens, and M.A. Boogaerts Measurement of serum cytokine levels in patients with myelodysplastic syndrome Leukemia 6 1992 1268 1272 (Pubitemid 23054024)
28. D.Y. Zang, R.G. Goodwin, M.R. Loken, E. Bryant, and H.J. Deeg Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis Blood 98 2001 3058 3065
29. M. Kitagawa, M. Takahashi, and S. Yamaguchi Expression of inducible nitric oxide synthase (NOS) in bone marrow cells of myelodysplastic syndromes Leukemia 13 1999 699 703 (Pubitemid 29243619)
30. C. Selleri, T. Sato, A.M. Raiola, B. Rotoli, N.S. Young, and J.P. Maciejewski Induction of nitric oxide synthase is involved in the mechanism of fas-mediated apoptosis in haemopoietic cells Br J Haematol 99 1997 481 489 (Pubitemid 27519844)
31. S.M. Kornblau, D. McCue, N. Singh, C. Wenjing, Z. Estrov, and K.R. Coombes Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia Blood 116 2010 4241 4261
32. A.M. Risitano, J.P. Maciejewski, S. Green, M. Plasilova, W. Zeng, and N.S. Young In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing Lancet 364 2004 355 364 (Pubitemid 38970012)
33. N.S. Young, R.T. Calado, and P. Scheinberg Current concepts in the pathophysiology and treatment of aplastic anemia Blood 108 2006 2511 2521
34. J.N. Kochenderfer, S. Kobayashi, E.D. Wieder, C. Su, and J.J. Molldrem Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression Blood 100 2002 3639 3645 (Pubitemid 35303934)
35. M.W. Wlodarski, L. Gondek, Z. Nearman, C. O'Keefe, A. Rodriguez, and J.P. Maciejewski Molecular analysis of CTL responses in myelodysplastic syndrome and other bone marrow failure states [abstract] Leuk Res 29 2005 S21
36. M.W. Wlodarski, L.P. Gondek, and Z.P. Nearman Molecular strategies for detection and quantitation od clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome Blood 108 2006 2632 2641
37. M. Nishimura, T. Yamada, and T. Andoh Granulocyte colony-stimulating factor (G-CSF) dependent hematopoiesis with monosomy 7 in a patient with severe aplastic anemia after ATG/CsA/G-CSF combined therapy Int J Hematol 68 1998 203 211 (Pubitemid 28479944)
38. S. Nakao, H. Takamatsu, and T. Chuhjo Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia Blood 84 1994 4257 4261 (Pubitemid 24371930)
39. Y. Saunthararajah, R. Nakamura, and J.M. Nam HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome Blood 100 2002 1570 1574 (Pubitemid 34925129)
40. M.H. Raaijmakers, S. Mukherjee, and S. Guo Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia Nature 464 2010 852 857
41. G.R. Boocock, J.A. Morrison, and M. Popovic Mutations in SBDS are associated with Shwachman-Diamond syndrome Nat Genet 33 2003 97 101 (Pubitemid 36068690)
42. A. Jonasova, R. Neuwirtova, and J. Cermak Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow Br J Haematol 200 1998 304 309 (Pubitemid 28131061)
43. T. Yamada, H. Tsurumi, S. Kasahara, T. Hara, M. Sawada, and H. Moriwaki Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A J Cancer Res Clin Oncol 129 2003 485 491 (Pubitemid 37056156)
44. S.B. Killick, G. Mufti, and J.D. Cavenagh A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia Br J Haematol 120 2003 679 684 (Pubitemid 36255870)
45. S. Yazji, F.J. Giles, and A.-M. Tsimberidou Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes Leukemia 17 2003 2101 2106 (Pubitemid 37428374)
46. M. Stadler, U. Germing, and K.-O. Kliche A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes Leukemia 18 2009 460 465 (Pubitemid 38425859)
47. D.P. Steensma, A. Dispenzieri, and A. Terreri Predicting response to ATG for patients with myelodysplastic syndrome Blood 102 2003 3852
48. P.A. Broliden, I.M. Dahl, and R. Hast Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes Haematologica 91 2006 667 670 (Pubitemid 43799466)
49. W. Atoyebi, L. Bywater, L. Rawlings, S. Brunskill, and T.J. Littlewood Treatment of myelodysplasia with oral cyclosporin Clin Lab Haematol 24 2002 211 214 (Pubitemid 34989250)
50. J. Marsh, H. Schrezenmeier, and P. Marin Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anemia Working Party Blood 93 1999 2191 2195 (Pubitemid 29153619)
51. E.M. Sloand, M.J. Olnes, B. Weinstein, P. Scheinberg, and N.S. Young Alemtuzumab treatment of intermediate-1 (INT-1) myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions [abstract] Blood 114 2009 116